Transaction · 0001741533-26-000010
KNSAKiniksa Pharmaceuticals International, plc
Paolini John F.
Paolini John F., CMO, reported a transaction classified as exercise at Kiniksa Pharmaceuticals International, plc involving 2497.000000 shares. Reported holdings after the transaction were 68120.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
exerciseSEC transaction code MCMO
- Trade date
- Sep 01, 2026
- Filing date
- Sep 03, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
Filing warnings
Notes recorded with this filingmissing priceThe filing did not provide a usable price per share.
KNSA price since this filing
Daily closing prices, with the filing date and available return windowsKNSA · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -7.6%1w ago -0.8%1d ago -2.3%
Returns since7d -5.0%30d -5.8%90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001741533-26-000010 Class A Ordinary Share
- Transaction date
- Sep 01, 2026 Filed Sep 03, 2026, 08:43 PM · 2d delay
- Shares
- 2,497 sh Price unknown
- Estimated value
- — Computed from shares × price
- Holdings after
- 68,120 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership
Filing-only score
+2 points
Compact filing score computed from stored Form 4 facts. Version v1.
Neutral filing signal
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - missing_price-8 points
price_cents is null
Missing price reduces confidence in value-based signals.
Missing facts
Read the scoring methodology- price_cents
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
CHIEF MEDICAL OFFICER
Officer YesDirector No10% NoOther No
Footnotes & amended
- F1
Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
- F2
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
- F3
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting comme…
- F4
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025.
- F5
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.
- F6
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
- F7
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Related transactions
Same SEC filing0 other transactions
Recent company activity
KNSA0 recent txs